Biotech company Ariad Pharmaceuticals' (NASDAQ: ARIA) quest to gain EU approval for its Chronic Myeloid Leukemia (CML) drug Iclusig is almost complete. Today, the company announced that the EU's CHMP recommended that the European Commission officially approve the drug. Why then, given this good news, did Ariad's share price barely move following the announcement. Was the market largely expecting this approval? And looking longer term, who will Ariad have to compete with as it hopes to ramp up sales for its CML treatment? Health-care analyst Max Macaluso tackles these issues in the following video.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.